Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9Y606
UPID:
PUS1_HUMAN
Alternative names:
tRNA pseudouridine synthase 1; tRNA pseudouridine(38-40) synthase; tRNA pseudouridylate synthase I; tRNA-uridine isomerase I
Alternative UPACC:
Q9Y606; A8K877; B3KQC1; Q8WYT2; Q9BU44
Background:
Pseudouridylate synthase 1 homolog, known alternatively as tRNA pseudouridine synthase 1, plays a crucial role in the pseudouridylation of tRNAs and mRNAs, impacting positions in the anticodon stem and intron-containing tRNA. This enzyme's activity extends to mRNA, targeting sequences for pseudouridylation that influence mRNA splicing and 3'-end processing, and it regulates nuclear receptor activity via SRA1 mRNA pseudouridylation.
Therapeutic significance:
Linked to Myopathy with lactic acidosis and sideroblastic anemia 1, a rare disorder affecting skeletal muscle and bone marrow, understanding the role of Pseudouridylate synthase 1 homolog could open doors to potential therapeutic strategies.